

7 - P - 01

Introduction

- Post-Surgical Recurrence: Recurrence after curative surgery for Hidradenitis Suppurativa (HS)varies based on the surgical approach.
- Diverse Surgical Approaches: The choice between deroofing, limited, or extended excision can impact the recurrence rate.
- Significant Studies: Several studies highlight a post-surgery recurrence rate of up to 34%.
- Mehdizadeh et al. (JAAD 2015) → 27%
- Tang et al. en (Int World J, 2023) → 16.2%
- Ovadja et al. (Dermatol surg, 2020) → 11 %
- Riddle et al. (DermatolSurg 2021)→ 34%
- Bouazzi et al. (Dermatol Surg 2020)→ 20,1%

Materials 1 Methods

✤ Objective:

- Prospectively assess local recurrence rate at 6 and 12 months

Local recurrence = recurrence within the scar, in the 1 cm zone around the scar or in the form of a fistula communicating with the scar, regardless of the length of the fistula pathway

Secondary objective:

- Identify factors predictive of recurrence
- Identify factors associated with post-operative complications
- Data collected : Demographic, disease data; Time to wound healing
- ✤ Of which analyzed in this study:
- Recurrence at 6 months and one year
- DLQI data collected pre-operatively, at 1, 6 and 12 months after surgery



Recurrence rates following excision of hidradenitis suppurativa: Prospective analysis of 74 patients

A.-C. Ezanno¹, P. Guillem, A.-C. Fougerousse & RésoVerneuil (1) HIA Bégin, Surgery, St Mandé, France


				Results
		n (%)	Mean ± standard deviation	
Age (years)			32.3 ±9.13	
Female gender		54 (71)		♣100
BMI kg/m2			26.6 ±6	* 100
Smooking		50 (66)		76 or
Localization wide excision	Inguino-genital	38 (50)		
	Axillairy	30 (39.5)		
	Mixed*	5 (6.6)		Chai
	Other**	3 (3.9)		- Mear
Hurley stage	I	6 (7.9)		- Mear
	II	37 (48.7)		- Mear
	III	33 (43.4)		
ISH4 at inclusion			11.8 ±8	- Mear
DLQI at inclusion			14.3 ±6.86	- Mear
Treatment	Aucun	21 (27.6)		
	Antibiothérapie ponctuelle	5 (6.6)		
	Antibiothérapie au long cours	45 (59.2)		
	Biothérapie	5 (6.6)		
Wound size cm ³			41.3 ±75.2	
Time to compled healing (days)			86 ± 80	

Recurrence Statistics:

- 15 patients with postoperative recurrence (20%) - Timeline of Recurrence, 2 periods

- ✓ 0-6 months post-operatively: 18.4% recurrence (n=14)
- ✓ 6-12 months post-operatively: 7.7% recurrence (n=4)
- ✓ Overlap in Recurrence: Of those with recurrence between
- 6-12 months, 3 had a recurrence in the first 6 months.

Time to onset of recurrence: recurrence ++ within the first 6 months



Effect of Medical Treatment: Significant difference in recurrence between 0-6 months for patients not receiving medical treatment for HS (p=0.036)

✤ <u>DLQI Influence:</u> At 6 months and 1 year, a DLQI > 15 at enrollment significantly influenced recurrence (p=0.014 and p=0.011, respectively).



patients (69% female) nly with data at 1, 6 and 12 months

racteristics:

- n preoperative DLQI 14.3± 6.8
- n preoperative VAS 4.2±3
- n excision size 41.3±75.2 cm3
- n healing time 86±80 days

		No Recurrence (n=61) (80%)	Local Recurrence (n=15) (20%)	p-value	
years		32.1 (±9.6)	33 (±7)	0.34	
der	Women	42 (69%)	12(80%)	0.53	
	Men	19 (31%)	2 (20%)		
, kg/m²		26.8 (±6.3)	25.7 (±4.5)	0,88	
ker	non	23 (38%)	3 (20%)	1	
	oui	38 (62%)	12 (80%)	T	
before surgery		13.3 (±6.7)	18.3 (±6)	0.011	
before surgery		4 (±3)	5.5 (±3)	0.08	
		12 (±7.9)	11 (±8.5)	0.46	
ment at D0	no	15 (25%)	5 (33%)	0.57	
	yes	47 (75%)	10 (67%)		
M1		11.8 (±5.5)	17.1 (±5.7)	<0.001	
	No	30 (49%)	8 (53%)	0.77	
	yes	31 (51%)	7 (47%)		
M6		4.4 (±4.9)	9.3 (±7.6)	0.028	
ment M12	no	37 (61%)	13 (87%)	0.05	
	yes	24 (39%)	2 (13%)		
M12		4.2 (±4.8)	7.2 (±6.2)	0.15	

- Recurrence Rate: Similar to literature reports. & Higher risk within the first 6 months post-surgery. - Medical Management Value: Emphasizes the importance of medical management. & Limits HS recurrence at the 6-month mark.

Treatment Insights: Biologics vs. Antibiotherapy: - Limited data on biologics effectiveness - Unable to confirm if biotherapy reduces recurrence compared to long-term antibiotics

surgery. - Higher risk of HS recurrence identified.

Clinical Implications:

- Highlight the need for ongoing medical management. - Consideration of biotherapy effectiveness, though inconclusive in this study.



Discussion

Key Study Findings

♦ Quality of Life Impact - Patients with severely impaired quality of life pre-

- Patient-Specific Factors: Emphasize the importance of assessing and addressing pre-surgery quality of life.

Conclusion

Our study confirms

- Optimized Medical Management: is necessary

- Key role in limiting recurrence risk at 6 months

- Reasons for recurrence after excision of a HS lesion remain to be investigated